| Human endogenous retrovirus-K contributes to motor neuron disease W Li, MH Lee, L Henderson, R Tyagi, M Bachani, J Steiner, E Campanac, ... Science translational medicine 7 (307), 307ra153-307ra153, 2015 | 462 | 2015 |
| HIV-associated opportunistic infections of the CNS IL Tan, BR Smith, G von Geldern, FJ Mateen, JC McArthur The Lancet Neurology 11 (7), 605-617, 2012 | 247 | 2012 |
| Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project KR Carson, SD Newsome, EJ Kim, ND Wagner‐Johnston, G Von Geldern, ... Cancer 120 (16), 2464-2471, 2014 | 144 | 2014 |
| Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy O Stuve, PD Cravens, EM Frohman, JT Phillips, GM Remington, ... Neurology 72 (5), 396-401, 2009 | 142 | 2009 |
| The influence of nutritional factors on the prognosis of multiple sclerosis G Von Geldern, EM Mowry Nature Reviews Neurology 8 (12), 678-689, 2012 | 121 | 2012 |
| Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy C Warnke, G von Geldern, P Markwerth, T Dehmel, R Hoepner, R Gold, ... Annals of neurology 76 (6), 792-801, 2014 | 100 | 2014 |
| Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF C Warnke, M Stettner, V Lehmensiek, T Dehmel, AK Mausberg, ... Multiple Sclerosis Journal 21 (8), 1036-1044, 2015 | 80 | 2015 |
| Accumulation of class switched IgD− IgM− memory B cells in the cerebrospinal fluid during neuroinflammation S Cepok, G von Geldern, V Grummel, S Hochgesand, H Celik, ... Journal of neuroimmunology 180 (1-2), 33-39, 2006 | 73 | 2006 |
| Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis S Cepok, H Schreiber, S Hoffmann, D Zhou, O Neuhaus, G von Geldern, ... Archives of neurology 66 (10), 1216-1223, 2009 | 48 | 2009 |
| Dietary interventions in multiple sclerosis: development and pilot-testing of an evidence based patient education program K Riemann-Lorenz, M Eilers, G Von Geldern, KH Schulz, S Köpke, ... PLoS One 11 (10), e0165246, 2016 | 46 | 2016 |
| PML-IRIS in a patient treated with brentuximab G von Geldern, CA Pardo, PA Calabresi, SD Newsome Neurology 79 (20), 2075-2077, 2012 | 38 | 2012 |
| Derivation of neural stem cells from human adult peripheral CD34+ cells for an autologous model of neuroinflammation T Wang, E Choi, MCG Monaco, E Campanac, M Medynets, T Do, P Rao, ... PloS one 8 (11), e81720, 2013 | 36 | 2013 |
| Pilot intervention to promote tolerance for uncertainty in early multiple sclerosis. IR Molton, E Koelmel, M Curran, G von Geldern, A Ordway, KN Alschuler Rehabilitation psychology 64 (3), 339, 2019 | 28 | 2019 |
| Longitudinal assessment of hand function in individuals with multiple sclerosis SD Newsome, G von Geldern, H Shou, M Baynes, RER Marasigan, ... Multiple sclerosis and related disorders 32, 107-113, 2019 | 27 | 2019 |
| Viral load determines the B‐cell response in the cerebrospinal fluid during human immunodeficiency virus infection S Cepok, G von Geldern, T Nolting, V Grummel, R Srivastava, D Zhou, ... Annals of Neurology: Official Journal of the American Neurological …, 2007 | 22 | 2007 |
| Effectiveness of alternative dose fingolimod for multiple sclerosis EE Longbrake, D Kantor, S Pawate, MJ Bradshaw, G Von Geldern, ... Neurology: Clinical Practice 8 (2), 102-107, 2018 | 18 | 2018 |
| Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med 7: 307ra153 W Li, MH Lee, L Henderson, R Tyagi, M Bachani, J Steiner, E Campanac, ... | 18 | 2015 |
| Immune mediated diseases and immune modulation in the neurocritical care unit G von Geldern, T McPharlin, K Becker Neurotherapeutics 9 (1), 99-123, 2012 | 16 | 2012 |
| A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: the design of … AL Kratz, KN Alschuler, DM Ehde, G von Geldern, R Little, S Kulkarni, ... Contemporary Clinical Trials 84, 105821, 2019 | 12 | 2019 |
| Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1. 0–Fatigue (MS) 8a P Kamudoni, J Johns, KF Cook, R Salem, S Salek, J Raab, R Middleton, ... Multiple Sclerosis and Related Disorders 54, 103117, 2021 | 11 | 2021 |
